-
1.发明授权公开(公告)号：US08058418B2
公开(公告)日：2011-11-15
申请号：US11981664
申请日：2007-10-30
IPC分类号： C12N15/11
CPC分类号： C07K16/2875 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/241 , C07K2317/21 , C07K2317/51 , C07K2317/515 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/622 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： Compositions comprising polynucleotides encoding heavy and light chains of antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of making such antibodies are described.
摘要翻译： 描述了包含编码与骨保护蛋白配体（OPGL）相互作用的抗体的重链和轻链的多核苷酸的组合物。 描述制备这种抗体的方法。
-
公开(公告)号：US07364736B2
公开(公告)日：2008-04-29
申请号：US10180648
申请日：2002-06-25
IPC分类号： A61K39/395
CPC分类号： C07K16/2875 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/241 , C07K2317/21 , C07K2317/51 , C07K2317/515 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/622 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.
摘要翻译： 描述了与骨保护素配体（OPGL）相互作用的抗体。 描述了通过向OPGL施用药学有效量的抗体来治疗骨质疏松症的方法。 描述使用OPGL抗体检测样品中OPGL的量的方法。
-
公开(公告)号：US08409578B2
公开(公告)日：2013-04-02
申请号：US13296201
申请日：2011-11-14
IPC分类号： A61K39/395
CPC分类号： C07K16/2875 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/241 , C07K2317/21 , C07K2317/51 , C07K2317/515 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/622 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.
摘要翻译： 描述了与骨保护素配体（OPGL）相互作用的抗体。 描述了通过向OPGL施用药学有效量的抗体来治疗骨质疏松症的方法。 描述使用OPGL抗体检测样品中OPGL的量的方法。
-
公开(公告)号：US20120087923A1
公开(公告)日：2012-04-12
申请号：US13296201
申请日：2011-11-14
IPC分类号： A61K39/395 , A61P19/08
CPC分类号： C07K16/2875 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/241 , C07K2317/21 , C07K2317/51 , C07K2317/515 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/622 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.
摘要翻译： 描述了与骨保护素配体（OPGL）相互作用的抗体。 描述了通过向OPGL施用药学有效量的抗体来治疗骨质疏松症的方法。 描述使用OPGL抗体检测样品中OPGL的量的方法。
-
公开(公告)号：US20090274688A1
公开(公告)日：2009-11-05
申请号：US11981664
申请日：2007-10-30
IPC分类号： A61K39/395 , A61K31/711 , C12N15/63 , C12N5/10 , C12P21/02 , A61P19/00 , G01N33/536 , C07K16/24
CPC分类号： C07K16/2875 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/241 , C07K2317/21 , C07K2317/51 , C07K2317/515 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/622 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.
摘要翻译： 描述了与骨保护素配体（OPGL）相互作用的抗体。 描述了通过向OPGL施用药学有效量的抗体来治疗骨质疏松症的方法。 描述使用OPGL抗体检测样品中OPGL的量的方法。
-
公开(公告)号：US07411057B2
公开(公告)日：2008-08-12
申请号：US11128900
申请日：2005-05-12
申请人： Douglas C Hanson , Mark J Neveu , Eileen E Mueller , Jeffrey H Hanke , Steven C Gilman , C. Geoffrey Davis , Jose R Corvalan
发明人： Douglas C Hanson , Mark J Neveu , Eileen E Mueller , Jeffrey H Hanke , Steven C Gilman , C. Geoffrey Davis , Jose R Corvalan
CPC分类号： C07K16/2818 , A61K39/39558 , A61K2039/505 , C07K2317/21 , C07K2317/24 , G01N33/56972 , G01N33/6863
摘要： In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.
摘要翻译： 根据本发明，提供了针对人细胞毒性T淋巴细胞抗原4（CTLA-4）的完全人单克隆抗体。 提供了编码尼罗肽的序列和包含重链和轻链免疫球蛋白分子，特别是跨越互补决定区（CDR）的连续重链和轻链序列，特别是来自FR1和/或CDR1至CDR3和/或FR4内的重链和轻链序列。 还提供了具有相似结合特性的抗体和具有与本文公开的抗体相似功能的抗体（或其它拮抗剂）。
-
公开(公告)号：US08143379B2
公开(公告)日：2012-03-27
申请号：US11981824
申请日：2007-10-31
申请人： Douglas Charles Hanson , Mark Joseph Neveu , Eileen Elliott Mueller , Jeffrey Herbert Hanke , Steven Christopher Gilman , C. Geoffrey Davis , Jose Ramon Corvalan
发明人： Douglas Charles Hanson , Mark Joseph Neveu , Eileen Elliott Mueller , Jeffrey Herbert Hanke , Steven Christopher Gilman , C. Geoffrey Davis , Jose Ramon Corvalan
IPC分类号： C07K16/00 , A61K39/395
CPC分类号： C07K16/2818 , A61K39/39558 , A61K2039/505 , C07K2317/21 , C07K2317/24 , G01N33/56972 , G01N33/6863
摘要： In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.
摘要翻译： 根据本发明，提供了针对人细胞毒性T淋巴细胞抗原4（CTLA-4）的完全人单克隆抗体。 提供了编码核酸序列和包含重链和轻链免疫球蛋白分子，特别是跨越互补决定区（CDR）的连续重链和轻链序列，特别是来自FR1和/或CDR1至CDR3和/或FR4内的重链和轻链序列。 还提供了具有相似结合特性的抗体和具有与本文公开的抗体相似功能的抗体（或其它拮抗剂）。
-
8.发明授权Methods for expressing and recovering human monoclonal antibodies to CTLA-4 有权用于表达和回收CTLA-4的人单克隆抗体的方法公开(公告)号：US07109003B2
公开(公告)日：2006-09-19
申请号：US10612497
申请日：2003-07-01
申请人： Douglas Charles Hanson , Mark Joseph Neveu , Eileen Elliott Mueller , Jeffrey Herbert Hanke , Steven Christopher Gilman , C. Geoffrey Davis , Jose Ramon Corvalan
发明人： Douglas Charles Hanson , Mark Joseph Neveu , Eileen Elliott Mueller , Jeffrey Herbert Hanke , Steven Christopher Gilman , C. Geoffrey Davis , Jose Ramon Corvalan
CPC分类号： C07K16/2818 , A61K39/39558 , A61K2039/505 , C07K2317/21 , C07K2317/24 , G01N33/56972 , G01N33/6863
摘要： In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.
摘要翻译： 根据本发明，提供了针对人细胞毒性T淋巴细胞抗原4（CTLA-4）的完全人单克隆抗体。 提供了编码尼罗肽的序列和包含重链和轻链免疫球蛋白分子，特别是跨越互补决定区（CDR）的连续重链和轻链序列，特别是来自FR1和/或CDR1至CDR3和/或FR4内的重链和轻链序列。 还提供了具有相似结合特性的抗体和具有与本文公开的抗体相似功能的抗体（或其它拮抗剂）。
-
9.发明授权公开(公告)号：US08491895B2
公开(公告)日：2013-07-23
申请号：US13399448
申请日：2012-02-17
申请人： Douglas Charles Hanson , Mark Joseph Neveu , Eileen Elliott Mueller , Jeffrey Herbert Hanke , Steven Christopher Gilman , C. Geoffrey Davis , Jose Ramon Corvalan
发明人： Douglas Charles Hanson , Mark Joseph Neveu , Eileen Elliott Mueller , Jeffrey Herbert Hanke , Steven Christopher Gilman , C. Geoffrey Davis , Jose Ramon Corvalan
IPC分类号： A61K39/395
CPC分类号： C07K16/2818 , A61K39/39558 , A61K2039/505 , C07K2317/21 , C07K2317/24 , G01N33/56972 , G01N33/6863
摘要： In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.
摘要翻译： 根据本发明，提供了针对人细胞毒性T淋巴细胞抗原4（CTLA-4）的完全人单克隆抗体。 提供了编码核酸序列和包含重链和轻链免疫球蛋白分子，特别是跨越互补决定区（CDR）的连续重链和轻链序列，特别是来自FR1和/或CDR1至CDR3和/或FR4内的重链和轻链序列。 还提供了具有相似结合特性的抗体和具有与本文公开的抗体相似功能的抗体（或其它拮抗剂）。
-
公开(公告)号：US20120148597A1
公开(公告)日：2012-06-14
申请号：US13399448
申请日：2012-02-17
申请人： Douglas Charles Hanson , Mark Joseph Neveu , Eileen Elliott Mueller , Jeffrey Herbert Hanke , Steven Christopher Gilman , C. Geoffrey Davis , Jose Ramon Corvalan
发明人： Douglas Charles Hanson , Mark Joseph Neveu , Eileen Elliott Mueller , Jeffrey Herbert Hanke , Steven Christopher Gilman , C. Geoffrey Davis , Jose Ramon Corvalan
IPC分类号： A61K39/395 , C12N15/13 , A61P35/00 , C07K16/46 , C12N5/10 , C12N15/63 , A01K67/027 , A01H5/00 , C12N5/20 , C07K16/28 , C12P21/02
CPC分类号： C07K16/2818 , A61K39/39558 , A61K2039/505 , C07K2317/21 , C07K2317/24 , G01N33/56972 , G01N33/6863
摘要： In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.
摘要翻译： 根据本发明，提供了针对人细胞毒性T淋巴细胞抗原4（CTLA-4）的完全人单克隆抗体。 提供了编码核酸序列和包含重链和轻链免疫球蛋白分子，特别是跨越互补决定区（CDR）的连续重链和轻链序列，特别是来自FR1和/或CDR1至CDR3和/或FR4内的重链和轻链序列。 还提供了具有相似结合特性的抗体和具有与本文公开的抗体相似功能的抗体（或其它拮抗剂）。
-
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.038 秒)
